Evidence map›Paper›PMID 39380117›Full record

ArticleBiomarker research2024

Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection.

Guoxin Wu, Samuel H Keller, Luca Sardo, Brian Magliaro, Paul Zuck, Carl J Balibar, Claire Williams, Liuliu Pan, Mark Gregory, Kathy Ton and 4 more

Abstract read
In one paragraph

Article in Biomarker research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Guoxin WuMRL, Merck & Co., Inc, Rahway, NJ, USA. Guoxin_wu@merck.com.
Samuel H KellerMRL, Merck & Co., Inc, Rahway, NJ, USA.
Luca SardoMRL, Merck & Co., Inc, Rahway, NJ, USA.
Brian MagliaroMRL, Merck & Co., Inc, Rahway, NJ, USA.
Paul ZuckMRL, Merck & Co., Inc, Rahway, NJ, USA.
Carl J BalibarMRL, Merck & Co., Inc, Rahway, NJ, USA.
Claire WilliamsNanoString Technologies, a Bruker Company, Seattle, WA, USA.
Liuliu PanNanoString Technologies, a Bruker Company, Seattle, WA, USA.
Mark GregoryNanoString Technologies, a Bruker Company, Seattle, WA, USA.
Kathy TonNanoString Technologies, a Bruker Company, Seattle, WA, USA.
Jill MaxwellMRL, Merck & Co., Inc, Rahway, NJ, USA.
Carol CheneyMRL, Merck & Co., Inc, Rahway, NJ, USA.
Tom RushMRL, Merck & Co., Inc, Rahway, NJ, USA.
Bonnie J HowellMRL, Merck & Co., Inc, Rahway, NJ, USA. Bonnie_howell@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLatency remains a major obstacle to finding a cure for HIV despite the availability of antiretroviral therapy. Due to virus dormancy, limited biomarkers are available to identify latent HIV-infected cells. Profiling of individual HIV-infected cells is needed to explore potential latency biomarkers and to study the mechanisms of persistence that maintain the HIV reservoir.

methodsSingle cell spatial transcriptomic characterization using the CosMx Spatial Molecular Imager platform was conducted to analyze HIV-infected cells in formalin-fixed paraffin-embedded sections of splenic tissue surgically obtained from an HIV-infected humanized mouse model. Regulation of over a thousand human genes was quantified in both viremic and aviremic specimens. In addition, in situ hybridization and immunohistochemistry were performed in parallel to identify HIV viral RNA- and p24-containing cells, respectively. Finally, initial findings from CosMx gene profiling were confirmed by isolating RNA from CD4 + T cells obtained from a person living with HIV on antiretroviral therapy following either PMA/Ionomycin or DMSO treatment. RNA was quantified using qPCR for a panel of targeted human host genes.

resultsSupervised cell typing revealed that most of the HIV-infected cells in the mouse spleen sections were differentiated CD4 + T cells. A significantly higher number of infected cells, 2781 (1.61%) in comparison to 112 (0.06%), and total HIV transcripts per infected cell were observed in viremic samples compared to aviremic samples, respectively, which was consistent with the data obtained from ISH and IHC. Notably, the expression of 55 genes was different in infected cells within tissue from aviremic animals compared to viremic. In particular, both spleen tyrosine kinase (SYK) and CXCL17, were expressed approximately 100-fold higher. This data was further evaluated against bulk RNA isolated from HIV-infected human primary CD4 + T cells. A nearly 6-fold higher expression of SYK mRNA was observed in DMSO-treated CD4 + T cells compared to those stimulated with PMA/Ionomycin.

conclusionThis study found that the CosMx SMI platform is valuable for assessing HIV infection and providing insights into host biomarkers associated with HIV reservoirs. Higher relative expression of the SYK gene in aviremic-infected cells from the humanized mouse HIV model was consistent with levels found in CD4 + T cells of aviremic donors.

Indexed as

BiomarkerCosMx SMIFFPEHIVqPCRSingle cellSYKTranscriptomic profiling

Identifiers

PMID39380117
PMCPMC11462831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.